Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) CFO Sells 1,000 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX) CFO Alisha Charlton sold 1,000 shares of Pro-Dex stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the completion of the transaction, the chief financial officer now owns 15,339 shares in the company, valued at $613,866.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Pro-Dex Stock Up 5.0 %

NASDAQ PDEX traded up $2.04 during trading hours on Friday, reaching $43.14. 14,828 shares of the company traded hands, compared to its average volume of 13,698. The company has a 50 day moving average of $28.86 and a two-hundred day moving average of $22.55. The stock has a market capitalization of $140.64 million, a PE ratio of 26.69 and a beta of 0.39. Pro-Dex, Inc. has a 12 month low of $15.70 and a 12 month high of $46.50. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, September 5th. The medical instruments supplier reported $0.46 EPS for the quarter, topping the consensus estimate of $0.35 by $0.11. The company had revenue of $15.03 million during the quarter. Pro-Dex had a return on equity of 16.74% and a net margin of 9.17%. As a group, equities analysts expect that Pro-Dex, Inc. will post 1.42 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 7th. Ascendiant Capital Markets increased their price target on Pro-Dex from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, September 9th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Perritt Capital Management Inc. lifted its stake in Pro-Dex by 43.3% in the first quarter. Perritt Capital Management Inc. now owns 6,000 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 1,813 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Pro-Dex by 7.9% in the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares during the last quarter. Bard Associates Inc. increased its holdings in shares of Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after acquiring an additional 2,031 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Pro-Dex by 5.1% in the second quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after purchasing an additional 3,067 shares during the period. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.